BiotechTube

VRDN-003 + Placebo

Phase 3Active
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thyroid Eye Disease

Conditions

Thyroid Eye Disease

Trial Timeline

Aug 27, 2024 → Dec 15, 2026

NCT ID
NCT06625398

About VRDN-003 + Placebo

VRDN-003 + Placebo is a phase 3 stage product being developed by Viridian Therapeutics for Thyroid Eye Disease. The current trial status is active. This product is registered under clinical trial identifier NCT06625398. Target conditions include Thyroid Eye Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT06812325Phase 3Active
NCT06625411Phase 3Active
NCT06625398Phase 3Active

Competing Products

20 competing products in Thyroid Eye Disease

See all competitors
ProductCompanyStageHype Score
MBX 2109MBX BiosciencesPhase 2
47
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionMBX BiosciencesPhase 2
47
PCO371 + PlaceboChugai PharmaceuticalPhase 1
33
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
41
efatutazone + paclitaxelDaiichi SankyoPhase 2
52
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
52
LenvatinibEisaiPre-clinical
23
LenvatinibEisaiPre-clinical
23
Lenvatinib + Placebo + LenvatinibEisaiPhase 3
77
Irofulven + capecitabineEisaiPhase 2
52
Lenvatinib + PlaceboEisaiPhase 3
77
LenvatinibEisaiApproved
85
LenvatinibEisaiPre-clinical
23
BexaroteneEisaiPhase 1
33
Lenvatinib + Lenvatinib matching placeboEisaiPhase 2
52
LenvatinibEisaiPhase 2
52
LENVATINIBEisaiPhase 2
52
E7080 capsuleEisaiPhase 2
52
Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort)EisaiPhase 2
52
Lenvatinib 24 mgEisaiPhase 2
52

Other Products from Viridian Therapeutics

VRDN-003 + PlaceboPhase 3
72
VRDN-003 + PlaceboPhase 3
72
VRDN-001 Phase 3 Cohort (THRIVE) + VRDN-001 PlaceboPhase 3
72
Intervention/TreatmentPhase 3
72
VRDN-001 10 mg/kg + VRDN-001 3 mg/kgPhase 3
72